Wavelength is a customer-focused backward-integrated world-class developer and manufacturer of Active Pharmaceutical Ingredients (APIs). It is the independent company of choice for pharmaceutical industry leaders that require advanced API solutions and reliable supply to gain sustainable competitive advantage. The company provides a consistent supply of high-quality APIs and has been in business since 1987. With a global outreach and scale, Wavelength's business is significantly focused in the US, EU, and JP markets. They offer peace of mind and ease of doing business with their differentiated products and services, which include injectables, inhalables, highly potent, cytotoxic, and controlled substances. They provide scale from pre-clinical grams to multi-ton commercial scale and ensure full compliance with consistent quality, regulatory compliance, and exceptional customer service. Wavelength boasts a 33-year exceptional regulatory track record with over 100 audits in the past five years. They are committed to their customers with an experienced and accessible management team and provide custom API development and manufacturing services. Their global presence includes 250 customers in 50 countries with a head office, production, and R&D in Israel, and additional sales office, production, and R&D in India, and a sales office in the USA. Wavelength offers a wide range of APIs, including newly developed products with DMF available for referencing, a wide range of commercially available APIs, products under active development, new candidates being considered for development, and a wide range of commercially available drug intermediates.